WO2026068504A2 - Nouveaux conjugués protéiques - Google Patents

Nouveaux conjugués protéiques

Info

Publication number
WO2026068504A2
WO2026068504A2 PCT/EP2025/077289 EP2025077289W WO2026068504A2 WO 2026068504 A2 WO2026068504 A2 WO 2026068504A2 EP 2025077289 W EP2025077289 W EP 2025077289W WO 2026068504 A2 WO2026068504 A2 WO 2026068504A2
Authority
WO
WIPO (PCT)
Prior art keywords
protein
rbcs
variant
seq
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2025/077289
Other languages
English (en)
Other versions
WO2026068504A3 (fr
Inventor
Ashley Mark TOYE
Natalie DI BARTOLO
Jacob Smith
Alice HATHAWAY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Bristol
Original Assignee
University of Bristol
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2414030.3A external-priority patent/GB202414030D0/en
Priority claimed from GBGB2506147.4A external-priority patent/GB202506147D0/en
Application filed by University of Bristol filed Critical University of Bristol
Publication of WO2026068504A2 publication Critical patent/WO2026068504A2/fr
Publication of WO2026068504A3 publication Critical patent/WO2026068504A3/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne de nouveaux conjugués de protéines qui peuvent être utilisés pour marquer des globules rouges (GR) avec une ou plusieurs enzymes. Les conjugués et/ou les RBC marqués peuvent être utilisés pour administrer l'enzyme ou les enzymes dans des contextes thérapeutiques. L'invention concerne également un RBC marqué avec les conjugués protéiques et des procédés thérapeutiques utilisant les conjugués protéiques et/ou les RBC marqués.
PCT/EP2025/077289 2024-09-24 2025-09-24 Nouveaux conjugués protéiques Pending WO2026068504A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB2414030.3 2024-09-24
GBGB2414030.3A GB202414030D0 (en) 2024-09-24 2024-09-24 Novel protein conjugates
GBGB2506147.4A GB202506147D0 (en) 2025-04-25 2025-04-25 Novel protein conjugates
GB2506147.4 2025-04-25

Publications (2)

Publication Number Publication Date
WO2026068504A2 true WO2026068504A2 (fr) 2026-04-02
WO2026068504A3 WO2026068504A3 (fr) 2026-05-07

Family

ID=97598808

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2025/077289 Pending WO2026068504A2 (fr) 2024-09-24 2025-09-24 Nouveaux conjugués protéiques

Country Status (1)

Country Link
WO (1) WO2026068504A2 (fr)

Citations (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
EP0154316A2 (fr) 1984-03-06 1985-09-11 Takeda Chemical Industries, Ltd. Lymphokine chimiquement modifiée et son procédé de préparation
EP0401384A1 (fr) 1988-12-22 1990-12-12 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1994004678A1 (fr) 1992-08-21 1994-03-03 Casterman Cecile Immunoglobulines exemptes de chaines legeres
WO1994029351A2 (fr) 1993-06-16 1994-12-22 Celltech Limited Anticorps
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5624821A (en) 1987-03-18 1997-04-29 Scotgen Biopharmaceuticals Incorporated Antibodies with altered effector functions
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5831012A (en) 1994-01-14 1998-11-03 Pharmacia & Upjohn Aktiebolag Bacterial receptor structures
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
WO1999016873A1 (fr) 1997-09-26 1999-04-08 Arne Skerra Anticalines
WO1999054342A1 (fr) 1998-04-20 1999-10-28 Pablo Umana Modification par glycosylation d'anticorps aux fins d'amelioration de la cytotoxicite cellulaire dependant des anticorps
WO2000042072A2 (fr) 1999-01-15 2000-07-20 Genentech, Inc. Variants polypeptidiques ayant une fonction effectrice alteree
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6165745A (en) 1992-04-24 2000-12-26 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
WO2001004144A2 (fr) 1999-07-13 2001-01-18 Scil Proteins Gmbh Fabrication de proteines a feuillet plisse beta et a proprietes de liaison specifiques
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP1176195A1 (fr) 1999-04-09 2002-01-30 Kyowa Hakko Kogyo Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
WO2003035835A2 (fr) 2001-10-25 2003-05-01 Genentech, Inc. Compositions de glycoproteine
US20040161738A1 (en) 2000-05-26 2004-08-19 Arumugam Muruganandam Single-domain brain-targeting antibody fragments derived from llama antibodies
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
WO2004106368A1 (fr) 2003-05-28 2004-12-09 Scil Proteins Gmbh Generation de proteines de liaison de synthese sur la base de proteines de type ubiquitine
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
US9879090B2 (en) 2013-03-04 2018-01-30 INSERM (Institut National De La SantéEt De La Recherche Médicale Fusion proteins and immunoconjugates and uses thereof which are specific for glycophorin A
WO2019113224A1 (fr) 2017-12-05 2019-06-13 The Trustees Of The University Of Pennsylvania Protéines de fusion et anticorps ciblant des antigènes de globules rouges humains
WO2020132234A1 (fr) 2018-12-19 2020-06-25 President And Fellows Of Harvard College Procédés et compositions se rapportant à des formes améliorées d'érythropoïétine ciblée
WO2021053243A1 (fr) 2019-09-20 2021-03-25 The University Of Bristol Produit pour la thérapie et procédés
EP3615556B1 (fr) 2017-04-24 2021-06-09 Oxford University Innovation Limited Protéines et marqueurs protéiques avec une formation plus rapide de la liaison isopeptidique et leurs utilisations
US20220089685A1 (en) 2016-11-16 2022-03-24 Bayer Healthcare Llc Red blood cell targeted factor viii and method of using the same
US20220348637A1 (en) 2019-11-11 2022-11-03 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii
US20230106353A1 (en) 2020-03-13 2023-04-06 Oxford University Innovation Limited System for covalently linking proteins

Patent Citations (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
EP0154316A2 (fr) 1984-03-06 1985-09-11 Takeda Chemical Industries, Ltd. Lymphokine chimiquement modifiée et son procédé de préparation
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5648260A (en) 1987-03-18 1997-07-15 Scotgen Biopharmaceuticals Incorporated DNA encoding antibodies with altered effector functions
US5624821A (en) 1987-03-18 1997-04-29 Scotgen Biopharmaceuticals Incorporated Antibodies with altered effector functions
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
EP0401384A1 (fr) 1988-12-22 1990-12-12 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US6180370B1 (en) 1988-12-28 2001-01-30 Protein Design Labs, Inc. Humanized immunoglobulins and methods of making the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5585089A (en) 1988-12-28 1996-12-17 Protein Design Labs, Inc. Humanized immunoglobulins
US5693762A (en) 1988-12-28 1997-12-02 Protein Design Labs, Inc. Humanized immunoglobulins
US6350861B1 (en) 1992-03-09 2002-02-26 Protein Design Labs, Inc. Antibodies with increased binding affinity
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US6165745A (en) 1992-04-24 2000-12-26 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
WO1994004678A1 (fr) 1992-08-21 1994-03-03 Casterman Cecile Immunoglobulines exemptes de chaines legeres
US5759808A (en) 1992-08-21 1998-06-02 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
WO1994029351A2 (fr) 1993-06-16 1994-12-22 Celltech Limited Anticorps
US5831012A (en) 1994-01-14 1998-11-03 Pharmacia & Upjohn Aktiebolag Bacterial receptor structures
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO1999016873A1 (fr) 1997-09-26 1999-04-08 Arne Skerra Anticalines
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
WO1999054342A1 (fr) 1998-04-20 1999-10-28 Pablo Umana Modification par glycosylation d'anticorps aux fins d'amelioration de la cytotoxicite cellulaire dependant des anticorps
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
WO2000042072A2 (fr) 1999-01-15 2000-07-20 Genentech, Inc. Variants polypeptidiques ayant une fonction effectrice alteree
EP1176195A1 (fr) 1999-04-09 2002-01-30 Kyowa Hakko Kogyo Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
WO2001004144A2 (fr) 1999-07-13 2001-01-18 Scil Proteins Gmbh Fabrication de proteines a feuillet plisse beta et a proprietes de liaison specifiques
US20040161738A1 (en) 2000-05-26 2004-08-19 Arumugam Muruganandam Single-domain brain-targeting antibody fragments derived from llama antibodies
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
WO2003035835A2 (fr) 2001-10-25 2003-05-01 Genentech, Inc. Compositions de glycoproteine
WO2004106368A1 (fr) 2003-05-28 2004-12-09 Scil Proteins Gmbh Generation de proteines de liaison de synthese sur la base de proteines de type ubiquitine
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
US9879090B2 (en) 2013-03-04 2018-01-30 INSERM (Institut National De La SantéEt De La Recherche Médicale Fusion proteins and immunoconjugates and uses thereof which are specific for glycophorin A
US20220089685A1 (en) 2016-11-16 2022-03-24 Bayer Healthcare Llc Red blood cell targeted factor viii and method of using the same
EP3615556B1 (fr) 2017-04-24 2021-06-09 Oxford University Innovation Limited Protéines et marqueurs protéiques avec une formation plus rapide de la liaison isopeptidique et leurs utilisations
WO2019113224A1 (fr) 2017-12-05 2019-06-13 The Trustees Of The University Of Pennsylvania Protéines de fusion et anticorps ciblant des antigènes de globules rouges humains
WO2020132234A1 (fr) 2018-12-19 2020-06-25 President And Fellows Of Harvard College Procédés et compositions se rapportant à des formes améliorées d'érythropoïétine ciblée
WO2021053243A1 (fr) 2019-09-20 2021-03-25 The University Of Bristol Produit pour la thérapie et procédés
US20220348637A1 (en) 2019-11-11 2022-11-03 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii
US20230106353A1 (en) 2020-03-13 2023-04-06 Oxford University Innovation Limited System for covalently linking proteins

Non-Patent Citations (67)

* Cited by examiner, † Cited by third party
Title
"UniProt", Database accession no. Q76LX8
ACS SYNTH BIOL., vol. 9, no. 2, 19 December 2019 (2019-12-19), pages 191 - 197
AL-LAZIKANI ET AL., JMB, vol. 273, 1997, pages 927 - 948
ALTSCHUL S. F., J MOL EVOL, vol. 36, 1993, pages 290 - 300
ALTSCHUL, S.F ET AL., J MOL BIOL, vol. 215, 1990, pages 403 - 10
ANAL BIOCHEM., vol. 438, no. 1, 26 March 2013 (2013-03-26), pages 82 - 9
ARMSTEAD WM ET AL., J CEREB BLOOD FLOW METAB, vol. 29, no. 8, 13 May 2009 (2009-05-13), pages 1463 - 74
BATZER ET AL., NUCLEIC ACID RES., vol. 19, 1991, pages 5081
BEAUCAGE ET AL., TETRA. LETT, vol. 22, 1981, pages 1859
BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426
BROWN ET AL., METH. ENZYMOL, vol. 68, pages 109
BUSHELL ET AL., GENOME RES, vol. 18, no. 4, February 2008 (2008-02-01), pages 622 - 30
CORTEZ-RETAMOZO, V. ET AL., INT J CANCER, vol. 89, 2002, pages 456 - 62
COX, J. P. L. ET AL., EUR. J IMMUNOL., vol. 24, 1994, pages 827 - 836
DETALLE ET AL., ANTIMICROB AGENTS CHEMOTHER, vol. 60, 2016
DEVEREUX ET AL., NUCLEIC ACIDS RESEARCH, vol. 12, 1984, pages 387 - 395
DUMOULIN, M. ET AL., NATURE, vol. 424, 2003, pages 783 - 788
ECKERT ET AL., PCR METHODS AND APPLICATIONS, vol. 1, no. 17, 1991
FLETCHER ET AL., ACS SYNTHETIC BIOLOGY, vol. 1, no. 6, 2012, pages 240 - 250
FRIGUET ET AL., J. IMMUNOL. METHODS, vol. 77, no. 2, 1985, pages 305 - 319
GAO, WANDERSON, P. JMAJERUS, E. MTULEY, E. ASADLER, J. E: "Exosite interactions contribute to tension-induced cleavage of von Willebrand factor by the antithrombotic ADAMTS13 metalloprotease", PROC. NATL. ACAD. SCI. U.S.A., vol. 103, 2006, pages 19099 - 19104
GAO, WANDERSON, P. JMAJERUS, E. MTULEY, E. ASADLER, J. E: "Exosite interactions contribute to tension-induced cleavage of von Willebrand factor by the antithrombotic ADAMTS13 metalloprotease", PROC. NATL. ACAD., vol. 103, 2006, pages 19099 - 19105
GRAGA ET AL.: "Modifying ADAMTS13 to modulate binding of pathogenic autoantibodies of patients with acquired thrombotic thrombocytopenic purpura", HAEMATOL, vol. 105, 2019, pages 2619 - 2630
GROOT, RENS DEAJOY BARDHANNALISHA RAMROOPDAVID A. LANEJAMES T. B. CRAWLEY: "Essential Role of the Disintegrin-like Domain in ADAMTS13 Function", BLOOD, vol. 113, no. 22, 28 May 2009 (2009-05-28), pages 5609 - 16, XP086510126, DOI: 10.1182/blood-2008-11-187914
HABIB, ANALYTICAL BIOCHEMISTRY, vol. 438, 1 July 2013 (2013-07-01), pages 82 - 89
HANEL ET AL., ANAL. BIOCHEM., vol. 339, no. 1, 2005, pages 182 - 184
HARRINGTON ET AL., NAT GENET, vol. 15, 1997, pages 345
HUANG ET AL., CHEMICAL ENGINEERING SCIENCE, vol. 270, 15 April 2023 (2023-04-15), pages 118521
HUSTON ET AL., PROC. NATL. ACAD. SCI., vol. 85, 1988, pages 5879 - 5883
INNIS: "PCR Protocols: A Guide to Methods and Applications", 1990, ACADEMIC PRESS
JIAN, CUIJUAN XIAOLINGJIE GONGCHRISTOPHER G. SKIPWITHSHENG-YU JINHAU C. KWAANX. LONG ZHENG: "Gain-of-Function ADAMTS13 Variants That Are Resistant to Autoantibodies against ADAMTS13 in Patients with Acquired Thrombotic Thrombocytopenic Purpura", BLOOD, no. 16, 19 April 2012 (2012-04-19), pages 119, Retrieved from the Internet <URL:https://doi.ora/10.1182/blood-2011-12-399501>
JONES, P. ET AL., NATURE, vol. 321, 1986, pages 522 - 525
KARAMITROS ET AL., FRONT BIOENG BIOTECHNOL, vol. 9, 17 December 2021 (2021-12-17), pages 793985
KEEBLE AHTURKKI PSTOKES 5KHAIRIL ANUAR INARAHIKAINEN RHYTÖNEN VPHOWARTH M: "Approaching infinite affinity through engineering of peptide-protein interaction", PROC NATL ACAD SCI U S A., vol. 116, no. 52, 10 December 2019 (2019-12-10), pages 26523 - 26533, XP055723018, DOI: 10.1073/pnas.1909653116
LAUWEREYS, M. ET AL., EMBO J, vol. 17, 1998, pages 3512 - 3520
LEFRANC, M.-P, THE IMMUNOLOGIST, vol. 7, 1999, pages 132 - 136
LEFRANC, M.-P. ET AL., DEV. COMP. IMMUNOL, vol. 27, 2003, pages 55 - 77
MAJERUS, E. MZHENG, XTULEY, E. ASADLER, J. E: "Cleavage of the ADAMTS13 propeptide is not required for protease activity", 3 BIOL CHEM, vol. 278, 2003, pages 46643 - 46648
MATTILA ET AL., NUCLEIC ACIDS RES., vol. 19, 1991, pages 967
METHODSX, vol. 2, 8 October 2015 (2015-10-08), pages 385 - 91
NARANG ET AL., METH. ENZYMOL, vol. 68, 1979, pages 90
NGUYEN, A.T ET AL., SCIENCE, vol. 357, 2017, pages 6350
OHTSUKA ET AL., J. BIOL. CHEM., vol. 260, 1985, pages 2605 - 2608
PLAIMAUER, BARBARAKLAUS ZIMMERMANNDIRK VÖLKELGERHARD ANTOINERANDOLF KERSCHBAUMERPEGAH JENABMIHA FURLAN ET AL.: "Cloning, Expression, and Functional Characterization of the von Willebrand Factor-Cleaving Protease (ADAMTS13", BLOOD, vol. 100, no. 10, 15 November 2002 (2002-11-15), pages 3626 - 32, XP002979372, Retrieved from the Internet <URL:https://doi.orq/10.1182/blood-2002-05-1397> DOI: 10.1182/blood-2002-05-1397
PLESCHBERGER, M. ET AL., BIOCONJUGATE CHEM, vol. 14, 2003, pages 440 - 448
PROTEIN EXPR PURIF, vol. 213, January 2024 (2024-01-01), pages 106362
QUEEN ET AL., IMMUNOL. REV, vol. 89, 1986, pages 49 - 68
QUEEN, C. ET AL., PROC. NATL. ACAD. SEE. U.S.A, vol. 86, pages 10029 - 10033
RIECHMANN, L. ET AL., NATURE, vol. 332, 1998, pages 323 - 327
ROSENFELD ET AL., CELL, vol. 68, 1992, pages 143
ROSSOLINI ET AL., MOL. CELL. PROBES, vol. 8, 1994, pages 91 - 98
SAMBROOK, JRUSSELL, D: "Molecular Cloning: A Laboratory Manual", 2001, COLD SPRING HARBOR LABORATORY PRESS
SCHEU AHALIM SYTMETZNER FJMOHAMMED 5HOWARTH M: "NeissLock provides an inducible protein anhydride for covalent targeting of endogenous proteins", NAT COMMUN, vol. 12, no. 1, 29 January 2021 (2021-01-29), pages 717, XP055804699, DOI: 10.1038/s41467-021-20963-5
SCI REP, vol. 6, 11 August 2016 (2016-08-11), pages 31370
SHIELDS, R.L. ET AL., J. BIOL. CHEM., vol. 277, 2002, pages 26733 - 26740
SHIELDS, R.L. ET AL., J. BIOL. CHEN, vol. 276, 2001, pages 6591 - 6604
SMITH, ANNU. REV. MICROBIOL, vol. 49, 1995, pages 807
SMOLAREK ET AL., CELL MOL LIFE SCI, vol. 67, no. 19, 11 May 2010 (2010-05-11), pages 3371 - 87
STACHOWIAK, J. C ET AL.: "Membrane bending by protein-protein crowding", NAT CELL BIOL, vol. 14, 2012, pages 944 - 949
STIJLEMANS, B. ET AL., J BIOL CHEM, vol. 279, 2004, pages 1256 - 1261
SWAINSBURY ET AL., BIOCHIM BIOPHYS ACTA, vol. 1857, no. 12, December 2016 (2016-12-01), pages 1829 - 1839
TOMLINSON, I. M. ET AL., J. FOL. BIOL, vol. 227, 1992, pages 776 - 798
UMANA ET AL., NAT. BIOTECH, vol. 17, 1999, pages 176 - 180
WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546
WU ET AL., CELL REPORTS, vol. 37, 2021, pages 109869
ZAKERI, BIJAN ET AL.: "Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 109, no. 12, 2012, pages 690 - 7, XP055217264, DOI: 10.1073/pnas.1115485109
ZHANG,P., PAN, W., RUX, A. H., SACHAIS, B. S. ZHENG, X. L: "The cooperative activity between the carboxyl-terminal TSP1 repeats and the CUB domains of ADAMTS13 is crucial for recognition of von Willebrand factor under flow", BLOOD, vol. 110, 2007, pages 1887 - 1894

Similar Documents

Publication Publication Date Title
JP7587550B2 (ja) 第ｘｉ因子抗体および使用方法
Funk et al. A barbed end interference mechanism reveals how capping protein promotes nucleation in branched actin networks
JP6330088B2 (ja) 自己免疫および炎症疾患を処置するためのヒスチジルｔＲＮＡ合成酵素
EP2917388B1 (fr) Acides nucléiques codant pour des polypeptides chimériques pour criblage de banque
JP5522723B2 (ja) 新規ポリペプチド，アフィニティークロマトグラフィー用材，及びイムノグロブリンの分離及び／又は精製方法
ES2887078T3 (es) Variantes de ligasa diseñadas
US7488816B2 (en) Methods for obtaining thermostable enzymes, DNA polymerase I variants from Thermus aquaticus having new catalytic activities, methods for obtaining the same, and applications of the same
KR20210076082A (ko) Rna를 편집하기 위한 방법 및 조성물
SG10202110500TA (en) Modified membrane type serine protease 1 (mtsp-1) polypeptides and methods of use
CA2859502A1 (fr) Assemblage et commande de reseaux d&#39;unites lumineuses
CN109153711B (zh) 具有降低的l-谷氨酰胺酶活性和增强的稳定性的l-天冬酰胺酶变体和融合蛋白
CA2615151A1 (fr) Chimeres de polymerase-proteine de liaison adn
EP3177642B1 (fr) Anticorps de l&#39;angiopoïétine-like 4 et procédés d&#39;utilisation correspondants
JP2022119761A (ja) アニオン性界面活性剤耐性が向上したアマドリアーゼ
JP2025530892A (ja) 非遺伝毒性の細胞前処置のための組成物及び方法
Zhao et al. Leucyl-tRNA synthetase from the ancestral bacterium Aquifex aeolicus contains relics of synthetase evolution
JP2022539560A (ja) 配列決定反応のための重合酵素
US20070190538A1 (en) Chimeric polymerases
WO2026068504A2 (fr) Nouveaux conjugués protéiques
Crosby et al. Characterization of the functional domains of boar acrosin involved in nonenzymatic binding to homologous zona pellucida glycoproteins
Ahuja et al. Human carbamoyl‐phosphate synthetase: Insight into N‐acetylglutamate interaction and the functional effects of a common single nucleotide polymorphism
US20120135472A1 (en) Hot-start pcr based on the protein trans-splicing of nanoarchaeum equitans dna polymerase
US20080199447A1 (en) Catalytic domain of adam33 and methods of use thereof
JP2022520283A (ja) 細胞透過性トランスポザーゼ
Maier et al. Mixed reconstitution of mutated subunits of HIV‐1 reverse transcriptase coexpressed in Escherichia coli–two tags tie it up